Today

HRV and/or resting heart rate outside your band on 5 of the last 7 nights (HRV z-score -1.9).

Meta-analysis (51 RCTs): resting heart rate −2.2 bpm (DHA drives it); increased vagal HRV. Within wearable RHR-trend resolution over 8–12 weeks.

• ·Mild bleeding-time increase — caution with anticoagulants; stop 2 weeks pre-surgery.
• ·Atrial fibrillation signal at ≥4 g/day — stay ≤3 g.

3 of 4 early-warning signals fired at once: temperature, resting heart rate, respiratory rate, HRV.

Cochrane 2024: colds −2.4 days (95% CI −4.2 to −0.5; low certainty) when started within 24 h of symptoms — i.e., when your wearable flags a temperature/RHR deviation.

• ·Metallic taste, nausea. Never intranasal zinc (anosmia). Long-term high dose depletes copper.

Energy reserve or activity below your band on 4 of the last 7 days.

RCT: fatigue −48% vs −29% placebo in menstruating women with ferritin <50 µg/L. Deficiency lowers VO₂ max and raises RHR — very wearable-visible when corrected.

• ⚑Ferritin + CBC
• ·NEVER without ferritin + CBC — hemochromatosis affects ~1/250; excess iron is pro-oxidant.

Steps or active calories below your band on 4 of the last 7 days.

Ergogenic across every modality tested (aerobic endurance ES 0.22–0.63; peak power ES 0.27, 95% CI 0.08 to 0.47) but costs 45 min of total sleep (95% CI −61.5 to −29.0), 11 min of deep sleep (95% CI −18.5 to −4.3) and 9 min of extra sleep latency (95% CI 3.8 to 14.4) when taken too late.

• ·Sleep disruption is the dominant documented cost: −45.3 min total sleep time, −7.0% sleep efficiency, −11.4 min deep sleep
• ·Anxiety, jitteriness, tachycardia and palpitations, strongly dose-dependent and modulated by ADORA2A genotype
• ·Acutely raises blood pressure and delays post-exercise heart rate and blood pressure recovery

High strain on 3 of the last 7 days while recovery stayed below your band on 3: the pattern of training harder than you are repairing.

Adds 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg to 1RM strength (95% CI 0.64 to 4.33) over a training block, and speeds strength recovery at 72 h post-exercise (ES 0.7, 95% CI 0.2 to 1.3).

• ·Bloating, gas and cramping in lactose intolerance — switch to isolate or hydrolysate
• ·Acne flares are reported with whey in susceptible individuals
• ·No evidence of kidney harm in people with normal renal function, but high intakes are not appropriate in existing chronic kidney disease

HRV and/or resting heart rate outside your band on 5 of the last 7 nights (HRV z-score -1.9).

Best-evidenced ergogenic; a single high dose partially reversed cognitive deficits during sleep deprivation (2024 RCT). Buffers the consequences of poor recovery.

• ·Raises lab creatinine harmlessly; hydrate.

High strain on 3 of the last 7 days while recovery stayed below your band on 3: the pattern of training harder than you are repairing.

Cuts post-exercise soreness (WMD −0.56 VAS points, 95% CI −0.84 to −0.27) and creatine kinase (−137 U/L, 95% CI −239 to −36), and adds ~4.1° of range of motion (95% CI 1.45 to 6.75).

• ·Diarrhoea, nausea and abdominal distension at doses above ~1.5 g/day
• ·Drug-induced liver injury is documented: 10 DILIN cases, 1 fatal; 7 of 10 carried HLA-B*35:01 and piperine-containing products were implicated
• ·Increases oxalate excretion — avoid with a history of calcium-oxalate kidney stones